DEBBANE RAYMOND — SEC Form 4 filings
SEC reporting owner CIK 1053890. 18 Form 4 filings on record with FilingPulse; latest filed 2026-06-04.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2024-04-29 to 2026-06-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 8 legs across 5 filings — 2,058,959 shares, $2,722,625 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 15 legs across 6 filings — 4,280,932 shares, $82,886,388 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 17.
- Largest priced transaction: sale of 1,600,000 shares @ $41.65 ($66,640,000) in Scholar Rock Holding Corp, filed 2024-12-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | 10% owner | 3 | — | 6 legs · 2,009,433 sh · $82,397,639 | 2 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | Director | 11 | 8 legs · 2,058,959 sh · $2,722,625 | — | 15 |
| GLYCOMIMETICS INC (GLYC) | 10% owner | 4 | — | 9 legs · 2,271,499 sh · $488,749 | — |
Form 4 filings — DEBBANE RAYMOND
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-04 | 4 | LEXICON PHARMACEUTICALS, INC. (LXRX) | Option exercise (M): 89,312 @ $0 · Option exercise (M): 89,312 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | LEXICON PHARMACEUTICALS, INC. (LXRX) | Grant/award (A): 35,714 (derivative) @ $0 · Grant/award (A): 43,478 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | LEXICON PHARMACEUTICALS, INC. (LXRX) | Purchase (P): 2,000 @ $1.49 | EDGAR |
| 2026-02-25 | 4 | LEXICON PHARMACEUTICALS, INC. (LXRX) | Purchase (P): 100,000 @ $1.47 | EDGAR |
| 2026-02-23 | 4 | LEXICON PHARMACEUTICALS, INC. (LXRX) | Purchase (P): 50,000 @ $1.44 · Purchase (P): 100,000 @ $1.48 | EDGAR |
| 2026-02-18 | 4 | LEXICON PHARMACEUTICALS, INC. (LXRX) | Purchase (P): 57,952 @ $1.31 · Purchase (P): 76,857 @ $1.31 · Purchase (P): 133,688 @ $1.32 | EDGAR |
| 2026-02-06 | 4 | Scholar Rock Holding Corp (SRRK) jointly with Invus Global Management, LLC, Siren, L.L.C. | Option exercise/expiry (X): 1,575,008 @ $7.35 · Option exercise/expiry (X): 1,575,008 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | LEXICON PHARMACEUTICALS, INC. (LXRX) jointly with Invus Global Management, LLC, Siren, L.L.C., Artal Participations S.a r.l., Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend | Grant/award (A): 18,553,846 @ $1.30 · Grant/award (A): 3,846,154 @ $1.30 · Purchase (P): 1,538,462 @ $1.30 · Grant/award (A): 367,145.12 @ $65 | EDGAR |
| 2025-06-03 | 4 | LEXICON PHARMACEUTICALS, INC. (LXRX) | Grant/award (A): 103,806 (derivative) @ $0 · Grant/award (A): 89,312 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | LEXICON PHARMACEUTICALS, INC. (LXRX) | Option exercise (M): 36,810 @ $0 · Option exercise (M): 36,810 (derivative) @ $0 | EDGAR |
| 2024-12-12 | 4 | Scholar Rock Holding Corp (SRRK) jointly with Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Siren, L.L.C., Invus Global Management, LLC | Sale (S): 1,600,000 @ $41.65 | EDGAR |
| 2024-11-27 | 4 | Scholar Rock Holding Corp (SRRK) jointly with Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Siren, L.L.C., Invus Global Management, LLC | Sale (S): 208,272 @ $37.63 · Sale (S): 43,887 @ $38.43 · Sale (S): 126,442 @ $39.51 · Sale (S): 30,683 @ $40.14 · Sale (S): 149 @ $40.98 | EDGAR |
| 2024-08-09 | 4 | GLYCOMIMETICS INC (GLYC) jointly with Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Siren, L.L.C., Invus Global Management, LLC | Sale (S): 61,488 @ $0.18 · Sale (S): 260,873 @ $0.19 | EDGAR |
| 2024-08-07 | 4 | GLYCOMIMETICS INC (GLYC) jointly with Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Siren, L.L.C., Invus Global Management, LLC | Sale (S): 164,523 @ $0.19 · Sale (S): 55,732 @ $0.18 | EDGAR |
| 2024-08-05 | 4 | GLYCOMIMETICS INC (GLYC) jointly with Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Siren, L.L.C., Invus Global Management, LLC | Sale (S): 63,564 @ $0.22 · Sale (S): 286,200 @ $0.20 | EDGAR |
| 2024-07-30 | 4 | GLYCOMIMETICS INC (GLYC) jointly with Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Siren, L.L.C., Invus Global Management, LLC | Sale (S): 258,335 @ $0.24 · Sale (S): 363,949 @ $0.24 · Sale (S): 756,835 @ $0.22 | EDGAR |
| 2024-05-13 | 4 | LEXICON PHARMACEUTICALS, INC. (LXRX) | Grant/award (A): 44,906 (derivative) @ $0 · Grant/award (A): 36,810 (derivative) @ $0 | EDGAR |
| 2024-04-29 | 4 | LEXICON PHARMACEUTICALS, INC. (LXRX) | Option exercise (M): 8,032 @ $0 · Option exercise (M): 8,032 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1053890 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →